141 related articles for article (PubMed ID: 36624190)
1. Establishment of a risk stratification model based on the combination of post-treatment serum squamous cell carcinoma antigen levels and FIGO stage of cervical cancer for treatment and surveillance decision-making.
Shi L; Liu Y; Li J; Kou J; Ouyang Y; Chen F; Huang X; Huo L; Huang L; Cao X
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5999-6007. PubMed ID: 36624190
[TBL] [Abstract][Full Text] [Related]
2. A prognostic model using FIGO 2018 staging and MRI-derived tumor volume to predict long-term outcomes in patients with uterine cervical squamous cell carcinoma who received definitive radiotherapy.
Zang L; Chen Q; Lin A; Chen J; Zhang X; Fang Y; Wang M
World J Surg Oncol; 2023 Jul; 21(1):210. PubMed ID: 37475053
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of pretreatment serum squamous cell carcinoma antigen for prognostication and decision-making in patients with early-stage cervical cancer.
Huang XD; Huo LQ; Luo YS; Chen K; Li JY; Shi L; Huang L; Cao XP; Ou-Yang Y; Chen FP
Ther Adv Med Oncol; 2023; 15():17588359231165974. PubMed ID: 37025259
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of serum squamous cell carcinoma antigen in patients with early cervical squamous cell carcinoma].
Li D; Xu XX; Yan DD; Yuan SH; Lou HM
Zhonghua Zhong Liu Za Zhi; 2019 May; 41(5):357-362. PubMed ID: 31137169
[No Abstract] [Full Text] [Related]
5. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
Ma R; Zhang H; Zou L; Qu Y
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
[TBL] [Abstract][Full Text] [Related]
6. Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
Benito V; Lubrano A; Pérez-Regadera JF; Torné A; Gil-Moreno A; Tejerizo-Garcia Á; Vergés R; Díaz-Feijoo B;
Gynecol Oncol; 2021 Aug; 162(2):407-412. PubMed ID: 34119366
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of preoperative serum squamous cell carcinoma antigen level for lymph node metastasis in early-stage cervical squamous cell carcinoma.
Zhu C; Zhang W; Wang X; Jiao L; Chen L; Jiang J
Medicine (Baltimore); 2021 Aug; 100(33):e26960. PubMed ID: 34414964
[TBL] [Abstract][Full Text] [Related]
9. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis.
Choi KH; Lee SW; Yu M; Jeong S; Lee JW; Lee JH
J Gynecol Oncol; 2019 Jan; 30(1):e1. PubMed ID: 30479085
[TBL] [Abstract][Full Text] [Related]
10. Average log change rate of pretreatment squamous cell carcinoma antigen after concurrent chemoradiotherapy in stage IIIC1 cervical squamous cell carcinoma.
Cho O; Chun M; Chang SJ
Sci Rep; 2024 Apr; 14(1):8710. PubMed ID: 38622276
[TBL] [Abstract][Full Text] [Related]
11. Construction of refined staging classification systems integrating FIGO/T-categories and corpus uterine invasion for non-metastatic cervical cancer.
Huang XD; Chen K; Shi L; Luo YS; Ou-Yang Y; Li JY; Huo LQ; Huang L; Chen FP; Cao XP
Cancer Med; 2023 Jul; 12(14):15079-15089. PubMed ID: 37326385
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma.
Duk JM; Groenier KH; de Bruijn HW; Hollema H; ten Hoor KA; van der Zee AG; Aalders JG
J Clin Oncol; 1996 Jan; 14(1):111-8. PubMed ID: 8558185
[TBL] [Abstract][Full Text] [Related]
13. The Validity of Using Human Squamous Cell Carcinoma Associated Antigen and Cytokeratin 19 Fragment Antigen 21-1 to Predict Postoperative Adjuvant Radiotherapy for Nonbulky Early-Stage Squamous Cell Carcinoma of the Cervix.
Liu CZ; Zeng HX; Zhao JJ; Rong Y; Mo ZL; Li LA; Zhang JQ
Int J Gynecol Cancer; 2017 Jun; 27(5):994-1000. PubMed ID: 28498239
[TBL] [Abstract][Full Text] [Related]
14. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
15. Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as IB disease?
Ayhan A; Aslan K; Bulut AN; Akilli H; Öz M; Haberal A; Meydanli MM
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():209-214. PubMed ID: 31325847
[TBL] [Abstract][Full Text] [Related]
16. Serum squamous cell carcinoma antigen level and magnetic resonance imaging for the prognosis of locally advanced cervical cancer.
Gu LN; Yu JW; Jiang L; Liu TB; Xu Y
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):668-678. PubMed ID: 38305609
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in definitive radiotherapy of uterine cervical cancer.
Yalman D; Aras AB; Ozkök S; Duransoy A; Celik OK; Ozsaran Z; Haydaroğlu A
Eur J Gynaecol Oncol; 2003; 24(3-4):309-14. PubMed ID: 12807246
[TBL] [Abstract][Full Text] [Related]
18. Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis.
Xu D; Wang D; Wang S; Tian Y; Long Z; Ren X
Int J Gynecol Cancer; 2017 Nov; 27(9):1935-1942. PubMed ID: 28914639
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
Huang EY; Huang YJ; Chanchien CC; Lin H; Wang CJ; Sun LM; Tseng CW; Tsai CC; Ou YC; Fu HC; Chen HC; Hsu HC; Wang CY
Radiat Oncol; 2012 Jan; 7():13. PubMed ID: 22289572
[TBL] [Abstract][Full Text] [Related]
20. Added-value of texture analysis of ADC in predicting the survival of patients with 2018 FIGO stage IIICr cervical cancer treated by concurrent chemoradiotherapy.
Zhang X; Zhang Q; Guo J; Zhao J; Xie L; Zhang J; An J; Yu X; Zhao X
Eur J Radiol; 2022 May; 150():110272. PubMed ID: 35334244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
